FiercePharma20d
Xeris, stymied by forgetful physicians, partners with ADA to raise awareness of need for glucagon
The FDA approved Gvoke, a ready-to-use glucagon product, for the treatment of severe hypoglycemia in 2019. The format is potentially more convenient than traditional glucagon kits from the likes ...
pharmaphorum1d
FDA knocks back Zealand's dasiglucagon once again
Another drugs that may be used off-label for GHI include Xeris' Gvoke brand of glucagon in pre-filled syringe and pen injector formulations, which was approved in 2019 as a hypoglycaemia rescue ...
pharmaphorum6d
CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugar
In the US, Baqsimi is now competing head-to-head with Xeris’ Gvoke, pre-filled syringe and pen injector formulations of glucagon that don’t require the mixing steps and can be used in patients ...
CNN1y
Xeris Biopharma Holdings, Inc.
The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the ...